Bayer AG acquires 5.35 million Bayer CropScience shares, raising stake to 20.34%

What Bayer CropScience announced

Bayer CropScience Ltd filed a Regulation 10(6) disclosure with BSE on 13 July 2026, reporting an inter‑se transfer of equity shares between its two promoters – Bayer AG and Bayer CropScience AG. The filing states that Bayer AG acquired 53,54,030 equity shares from Bayer CropScience AG on 8 July 2026 under a block‑deal mechanism.

"The Acquirer is exempted from making an open offer in terms of Regulation 10(1)(a)(ii) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011."

The transaction was priced at INR 4,122.30 per share, bringing the total consideration to roughly Rs 2,207 crore (53,54,030 × 4,122.30). The filing confirms that all regulatory disclosures required under Regulation 10(5) and 10(6) were made within the prescribed timelines.

Details of the inter‑se transfer

• Acquirer: Bayer AG (promoter of Bayer CropScience Ltd).
• Seller: Bayer CropScience AG (co‑promoter).
• Date of acquisition: 8 July 2026.
• Number of shares transferred: 53,54,030 equity shares.
• Price per share: INR 4,122.30.
• Mechanism: Block‑deal, a standard exchange‑traded transaction for large volumes.

The filing notes that the acquisition represents 11.91% of the existing paid‑up share capital of Bayer CropScience Ltd on a fully‑diluted basis. Because both parties are promoters, the transaction qualifies for an exemption from the mandatory open‑offer requirement under SEBI’s takeover code.

Shareholding impact

The transfer effectively consolidates the promoter group’s holdings under Bayer AG, increasing its voting power and influence over corporate decisions. No new shares were issued; the transaction was a pure transfer of existing equity.

Key facts at a glance

Why this matters for investors

The acquisition does not dilute the share capital because it is a transfer between existing shareholders. However, the increase in Bayer AG’s stake to over 20% may affect the balance of power within the promoter group, potentially influencing future strategic decisions, board composition, and related‑party transactions. The exemption from an open offer means that minority shareholders did not receive a cash offer for their shares, a point that may be of interest to those monitoring corporate governance practices.

Regulatory compliance is confirmed: the filing was made under Regulation 10(5) on 1 July 2026 and the detailed disclosure under Regulation 10(6) on 13 July 2026, satisfying SEBI’s timeline requirements. No further approvals or consents are mentioned in the filing, indicating that the transaction was completed solely under the existing shareholder framework.

Conclusion

Bayer AG’s purchase of 53.54 lakh shares from Bayer CropScience AG on 8 July 2026 raises its ownership in Bayer CropScience Ltd to 20.34%, consolidating promoter control without diluting existing shareholders. The transaction is exempt from an open offer and has been duly disclosed to BSE in compliance with SEBI regulations. Investors now have a clearer view of the promoter shareholding structure, while any future changes will depend on subsequent corporate actions or regulatory filings.